Description

A systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF).

Cabergoline is highly effective and will help the majority of women begin having regular menstrual cycles after they begin taking it. In addition to this, over half of women who begin taking Cabergoline will be able to ovulate regularly as well.

Cabergoline is sometimes given to women who are not ovulating due to a high level of prolactin in her body. It can also be used for men who are having issues with their reproductive system due to high levels of prolactin as well.